^
    Back
    Association details:
    Biomarker:CEBPA mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) +
    cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) +
    idarubicin hydrochloride (Topoisomerase II inhibitor, DNA cross linking agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Medicine (Baltimore)
    Title:

    Transformation from acute promyelocytic leukemia to acute myeloid leukemia with a CEBPA double mutation: A case report and review of the literature

    Published date:
    02/05/2021
    Excerpt:
    In the fourth cycle of maintenance therapy, APL was transformed into AML with a CEBPA double mutation. After 1 cycle of 0, the patient achieved complete remission and received 3 cycles of idarubicin and cytarabine and three cycles of high-dose cytarabine as consolidation therapy.
    Secondary therapy:
    paclitaxel
    DOI:
    10.1097/MD.0000000000024385